TriNetX Announces CEO Gadi Lachman's Departure After 11 Years at the Helm

TriNetX CEO Gadi Lachman Announces Departure

In a significant leadership transition, Gadi Lachman, the founder and current CEO of TriNetX, the world's largest real-world data source, has announced his plans to resign from his operational role effective March 31, 2025. This move marks the end of an era that has seen Lachman shape and grow TriNetX into a pivotal player in the healthcare data landscape since its inception in 2014.

Lachman's journey with TriNetX began with the vision of creating a comprehensive platform that empowers clinical research by utilizing real-world data. Over the past eleven years, he has been at the forefront of this mission, guiding the company through its milestones and extensive growth phases. Acknowledging the support from employees, clients, and shareholders, Lachman expressed, "It has been an honor to build TriNetX and be part of such an outstanding team. With the talent and passion of our employees, I am very confident that TriNetX will continue to succeed."

Under his leadership, TriNetX has become a cornerstone of clinical research with access to data from over 25 countries, generating millions of queries monthly. The platform has revolutionized the clinical research process, enhancing the development of therapies and ultimately saving lives across various therapeutic areas.

During the transitional phase following Lachman's departure, Jeff Margolis, currently a director at TriNetX, will take on the role of Executive Chairman. This decision strives to ensure continuity in leadership and administration while the search for a new CEO is underway. Margolis reflected on his time working alongside Lachman, stating, "I had the great privilege to serve alongside Gadi on the board and worked with him for 11 years. On behalf of the board, we thank Gadi for shaping and leading TriNetX into the world's leading ecosystem for real-world data and evidence in the biosciences and broader healthcare sector."

In alignment with Lachman's departure, Joe Bress, a partner and Global Co-Head of Healthcare at Carlyle, TriNetX's primary investor, shared enthusiasm for continuing collaboration, highlighting Lachman's disciplined leadership style. Under his guidance, TriNetX maintained profitability even amidst high growth. "Gadi has built the company to an exciting point and paved the way for new leadership to take it into the next chapter of growth and success," he noted.

Despite this shift in leadership, TriNetX remains steadfast in its mission to advance global healthcare through the power of real-world data. The board, leadership team, and employees are united in their commitment to foster innovation and ensure success for customers and partners while building on Lachman’s remarkable legacy.

About TriNetX

TriNetX is a global network of healthcare organizations and life sciences companies focused on advancing real-world research and accelerating the development of new therapies. Through its self-service platform compliant with HIPAA, GDPR, and LGPD, TriNetX enables its global community to enhance clinical trial protocol designs, optimize study operations, clarify safety signals, and enrich the generation of real-world evidence. For more information, visit TriNetX or follow them on LinkedIn.